24 May 2021 - Results of early trial demonstrate 70% overall response rate in patients with KRAS mutant tumours, 44% overall response rate in KRAS wild type tumours and 52% overall response rate in all evaluable patients with a favourable safety profile.

Verastem today announced that the U.S. FDA granted breakthrough therapy designation for the combination of its investigational RAF/MEK inhibitor VS-6766, with defactinib, its FAK inhibitor, for the treatment of all patients with recurrent low-grade serous ovarian cancer regardless of KRAS status after one or more prior lines of therapy, including platinum-based chemotherapy.

Read Verastem press release